NTV Asset Management LLC Sells 10,644 Shares of Pfizer Inc. $PFE

NTV Asset Management LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 18.6% during the second quarter, Holdings Channel.com reports. The firm owned 46,591 shares of the biopharmaceutical company’s stock after selling 10,644 shares during the quarter. NTV Asset Management LLC’s holdings in Pfizer were worth $1,129,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. QRG Capital Management Inc. lifted its holdings in shares of Pfizer by 8.6% in the 2nd quarter. QRG Capital Management Inc. now owns 759,903 shares of the biopharmaceutical company’s stock worth $18,420,000 after purchasing an additional 59,948 shares in the last quarter. Corundum Group Inc. lifted its holdings in shares of Pfizer by 3.0% in the 2nd quarter. Corundum Group Inc. now owns 32,175 shares of the biopharmaceutical company’s stock worth $780,000 after purchasing an additional 934 shares in the last quarter. Franklin Street Advisors Inc. NC lifted its stake in Pfizer by 27.0% during the 2nd quarter. Franklin Street Advisors Inc. NC now owns 54,831 shares of the biopharmaceutical company’s stock valued at $1,329,000 after acquiring an additional 11,668 shares in the last quarter. Stock Yards Bank & Trust Co. lifted its stake in Pfizer by 0.6% during the 2nd quarter. Stock Yards Bank & Trust Co. now owns 93,054 shares of the biopharmaceutical company’s stock valued at $2,256,000 after acquiring an additional 551 shares in the last quarter. Finally, HighMark Wealth Management LLC lifted its stake in Pfizer by 123.7% during the 2nd quarter. HighMark Wealth Management LLC now owns 4,249 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 2,350 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on PFE shares. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Finally, Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $28.41.

Pfizer Trading Up 1.1%

Shares of Pfizer stock opened at $27.37 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The firm has a market cap of $155.59 billion, a PE ratio of 14.56, a P/E/G ratio of 0.88 and a beta of 0.55. The stock has a fifty day moving average price of $24.67 and a 200-day moving average price of $24.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the firm posted $0.60 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.